Katherine Peters

Overview:

Dr. Katy Peters, MD PhD FAAN is an associate professor of neurology and neurosurgery at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.   Her academic medical career started at Stanford University School of Medicine where she received an MD and PhD in Cancer Biology.  After completing a neurology residency at Johns Hopkins University and a fellowship in cognitive neurosciences, Katy joined the PRTBTC as a neuro-oncology fellow.  In 2009, she became a faculty member at PRTBTC.  With an amazing team of nursing and advanced practice providers, she actively sees and cares for patients with primary brain tumors.  Her research interests include supportive care for brain cancer patients, cognitive dysfunction in cancer patients, and physical function and activity of brain cancer patients.   While she runs clinical trials for the treatment of primary brain tumors, her key interest is on clinical trials that focus on the improvement of quality of life and cognition for brain tumor patients.   In 2019, the PRTBTC designated her as the Director of Supportive Care, thus furthering the PRTBTC and her committee to bettering the quality of life for brain tumor patients.   She is very active in teaching medical school students, residents, fellows, and advanced practice providers and is the Program Director of the PRTBRC neuro-oncology fellowship.     She is board certified by the American Board of Psychiatry and Neurology and the United Council of Neurologic Subspecialties for neuro-oncology.

Positions:

Associate Professor of Neurosurgery

Neurosurgery, Neuro-Oncology
School of Medicine

Associate Professor in Neurology

Neurology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2003

Stanford University

Ph.D. 2003

Stanford University

Intern, Medicine

Johns Hopkins University

Resident and Fellow in Neurology, Neurology

Johns Hopkins University

Fellow in Neuro-Oncology, Surgery

Duke University

Grants:

Ph 1/2 Trial for Patients with Newly Diagnosed High Grade Glioma Treated with Concurrent Radiation Therapy, Temozolomide, and BMX-001

Administered By
Neurosurgery, Neuro-Oncology
Awarded By
BioMimetix JV LLC
Role
Principal Investigator
Start Date
End Date

A Phase 1, Multicenter, Randomized, Controlled, Open-label, Perioperative Study of AG-120 and AG-881 in Subjects with Recurrent, Non-enhancing, IDH1 Mutant, Low-grade Glioma. (AG120-881-C-001)

Administered By
Duke Cancer Institute
Awarded By
Agios Pharmaceuticals, Inc.
Role
Principal Investigator
Start Date
End Date

Functional Capacity and Physical Function in Glioblastoma Patients Treated with or without Tumor-Treating Fields

Administered By
Duke Cancer Institute
Awarded By
Novocure
Role
Principal Investigator
Start Date
End Date

A Study for Management of Ocular Side Effects in Subjects with EGFR-Amplified Glioblastoma receiving Depatuxizumab Mafodotin

Administered By
Duke Cancer Institute
Awarded By
AbbVie Inc.
Role
Principal Investigator
Start Date
End Date

A randomized phase 2 single blind study of temozolomide plus radiation therapy combined with nivolumab or placebo in newly diagnosed adult subjects with MGMT-methylated glioblastoma (BMS CA209-548)

Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Role
Principal Investigator
Start Date
End Date

Publications:

RADIOPROTECTION OF BRAIN WHITE MATTER BY THE CATALYTIC MnSOD MIMIC/ANTIOXIDANT, BMX-001

Authors
Weitzel, D; Ashcraft, K; Liu, C; Li, W; Buckley, A; Rodriguez, R; Wetzel, W; Spazojevic, I; Tovmasyan, A; Peters, K; Batinic-Haberle, I; Dewhirst, M
MLA Citation
Weitzel, Douglas, et al. “RADIOPROTECTION OF BRAIN WHITE MATTER BY THE CATALYTIC MnSOD MIMIC/ANTIOXIDANT, BMX-001.” Neuro Oncology, vol. 15, OXFORD UNIV PRESS INC, 2013, pp. 5–6.
URI
https://scholars.duke.edu/individual/pub952393
Source
wos
Published In
Neuro Oncology
Volume
15
Published Date
Start Page
5
End Page
6

RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse events.

Targeted therapy has gained mainstream attention with notable successes against specific genetic mutations in many cancers. One particular mutation, the BRAF V600E mutation, is present in a small subset of gliomas in adults. Although clinical experience and trial data of RAF-targeted therapy in adults with glioma are lacking at this time, the poor prognosis of adult high-grade glioma has led neuro-oncology practitioners to consider the use of targeted therapy in these patients. In this manuscript, we describe the use of RAF and MEK inhibitors in adults with recurrent glioma. We discuss the utility of these agents, describe their toxicities, and give examples of management strategies. Given the significant toxicities of RAF and MEK inhibitors, along with the long potential duration of treatment, neuro-oncology providers should counsel patients carefully before initiating therapy and monitor them closely while undergoing treatment with RAF-targeted therapy.
Authors
Schreck, KC; Patel, MP; Wemmer, J; Grossman, SA; Peters, KB
MLA Citation
Schreck, Karisa C., et al. “RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse events.Neurooncol Pract, vol. 7, no. 4, July 2020, pp. 369–75. Pubmed, doi:10.1093/nop/npaa006.
URI
https://scholars.duke.edu/individual/pub1454512
PMID
32765888
Source
pubmed
Published In
Neuro Oncology Practice
Volume
7
Published Date
Start Page
369
End Page
375
DOI
10.1093/nop/npaa006

REVIEW AND META-ANALYSIS OF NAUSEA AND VOMITING TRIALS FOR MALIGNANT GLIOMAS

Authors
Affronti, M; Randazzo, D; Woodring, S; McSherry, F; Healy, P; Herndon, J; Weant, M; Miller, E; Lipp, E; Friedman, H; Peters, K
MLA Citation
Affronti, Mary, et al. “REVIEW AND META-ANALYSIS OF NAUSEA AND VOMITING TRIALS FOR MALIGNANT GLIOMAS.” Neuro Oncology, vol. 20, OXFORD UNIV PRESS INC, 2018, pp. 218–218.
URI
https://scholars.duke.edu/individual/pub1376062
Source
wos
Published In
Neuro Oncology
Volume
20
Published Date
Start Page
218
End Page
218

Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population.

Authors
Mellinghoff, IK; Peters, KB; Cloughesy, TF; III, BHA; Maher, EA; Janku, F; Cote, GM; De La Fuente, MI; Clarke, JL; Le, K; Liu, L; Yuen, M; Arnofsky, M; Hassan, I; Steelman, L; Pandya, SS; Wen, PY
URI
https://scholars.duke.edu/individual/pub1467314
Source
wos-lite
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
38
Published Date

Characterization of Radiation Necrosis in Long-Term Survivors (LTS) of Primary Glioblastoma

Authors
Levacic, D; Peters, K
MLA Citation
Levacic, Danijela, and Katherine Peters. “Characterization of Radiation Necrosis in Long-Term Survivors (LTS) of Primary Glioblastoma.” Neurology, vol. 80, LIPPINCOTT WILLIAMS & WILKINS, 2013.
URI
https://scholars.duke.edu/individual/pub1247885
Source
wos
Published In
Neurology
Volume
80
Published Date

Research Areas:

Brain--Tumors
Cancer
Cognition
Quality of Life
Supratentorial brain tumors